KIARA DEEM: Open Payments
NPI 1447627856 · SAN TAN VALLEY, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$734 in 44 payments from 11 companies in 2025. Trend: 2023 $830 · 2024 $811 · 2025 $734
Food & beverage: $734
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $152 |
| AstraZeneca Pharmaceuticals LP | 9 | $143 |
| Astellas Pharma US Inc | 5 | $99 |
| Novo Nordisk Inc | 4 | $78 |
| Abbott Laboratories | 4 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $71 |
| Lilly USA, LLC | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 1 | $31 |
| Optinose US, Inc. | 1 | $18 |
| Merck Sharp & Dohme LLC | 1 | $17 |
Products named: AIRSUPRA, QULIPTA, Veozah, CAPLYTA, FREESTYLE LIBRE 3, Ozempic, MOUNJARO, Wegovy.
Industry payments across AZ — which companies pay providers there.
